Vir Biotechnology (VIR) Stock Price, News & Analysis

Company Overview

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $6.01 to $6.26
• 50-Day Range: $5.19 to $9.85
• 52-Week Range: $4.95 to $14.45
• Volume: 876,317 shs
• Average Volume: 1.34 million shs
• Market Capitalization: $844.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.57
• Consensus Rating: Moderate Buy

Vir Biotechnology Stock Analysis - MarketRank™

Vir Biotechnology scored higher than 52% of companies evaluated by MarketBeat, and ranked 455th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Vir Biotechnology has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vir Biotechnology are expected to grow in the coming year, from ($3.92) to ($3.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vir Biotechnology is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vir Biotechnology is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vir Biotechnology has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.56% of the float of Vir Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Vir Biotechnology has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Vir Biotechnology has recently increased by 28.30%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vir Biotechnology does not currently pay a dividend.

Dividend Growth

Vir Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.56% of the float of Vir Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Vir Biotechnology has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Vir Biotechnology has recently increased by 28.30%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.90

News Sentiment

Vir Biotechnology has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Vir Biotechnology this week, compared to 5 articles on an average week.

Search Interest

Only 5 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $663,525.00 in company stock.

Percentage Held by Insiders

15.60% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VIR Stock Analysis - Frequently Asked Questions

How have VIR shares performed this year?

Vir Biotechnology's stock was trading at $7.34 at the beginning of 2025. Since then, VIR shares have decreased by 16.6% and is now trading at $6.12.
View the best growth stocks for 2025 here.

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology, Inc. (NASDAQ:VIR) issued its earnings results on Wednesday, February, 26th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.09. The firm earned $12.37 million during the quarter, compared to analysts' expectations of $8.14 million. Vir Biotechnology had a negative trailing twelve-month return on equity of 36.71% and a negative net margin of 678.40%.
Read the conference call transcript.

When did Vir Biotechnology IPO?

Vir Biotechnology (VIR) raised $149 million in an initial public offering on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

Who are Vir Biotechnology's major shareholders?

Top institutional shareholders of Vir Biotechnology include Rhumbline Advisers (0.17%), State of Alaska Department of Revenue (0.04%), GAMMA Investing LLC (0.03%) and Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Backer Marianne De, George A Scangos, Phillip Pang, Howard Horn, Ann M Hanly, Steven J Rice, Sung Lee, Verneuil Vanina De, Brent Sabatini, Saira Ramasastry, Janet Napolitano and Charles Elliott Sigal.
View institutional ownership trends.

How do I buy shares of Vir Biotechnology?

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vir Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vir Biotechnology investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Home Depot (HD), Moderna (MRNA) and Visa (V).

Company Calendar

• Last Earnings: 2/26/2025
• Today: 4/26/2025
• Next Earnings (Estimated): 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VIR
• CIK: 1706431
• Web: www.vir.bio
• Phone: 415-906-4324
• Fax: N/A
• Employees: 580
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $33.57
• High Stock Price Target: $110.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: +448.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-615,060,000.00
• Net Margins: -678.40%
• Pretax Margin: -685.83%
• Return on Equity: -36.71%
• Return on Assets: -31.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.94
• Quick Ratio: 8.94

Sales & Book Value

• Annual Sales: $63.71 million
• Price / Sales: 13.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.82 per share
• Price / Book: 0.52

Miscellaneous

• Outstanding Shares: 138,064,000
• Free Float: 116,236,000
• Market Cap: $844.95 million
• Optionable: Optionable
• Beta: 1.14